Kymeris Therapeutics is a Canadian biotech firm based in Toronto, Ontario, that is revolutionizing cancer treatment with its next-generation cellular immunotherapy platform against solid cancer. The company is in the late discovery phase of its Eukaryotic Immunotherapeutic Cancer Vaccine, which has demonstrated potent therapeutic effects on solid cancers, even at a metastatic level. Kymeris has achieved proofs of principle in four pre-clinical murine models and created multiple derivatives that express or secrete constructs of therapeutic interest.
Next-Generation Cellular Immunotherapy Platform
Kymeris Therapeutics is developing a next-generation cellular immunotherapy platform that targets solid cancer. The platform has demonstrated the following features to date:
- Effect on “Cold” Tumors – Tumors that are of low immuno-reactivity are often referred to as “cold” tumors. Kymeris’ cellular immunotherapy platform has shown a significant effect on these tumors, making it a promising treatment option for patients with such tumors.
- Overcomes Tumor Microenvironment Defenses – The agents developed by Kymeris can infiltrate the tumor microenvironment (TME) and reactivate tolerogenic dendritic cells (DCs), leading to a strong cellular immune response (Th-1 profile). This type of immune response is capable of destroying cancerous cells and can potentially improve patient outcomes.
- Flexible Tumor-Centric Drug Delivery – Kymeris’ platform allows for complex transgenic payloads of molecules to be expressed or secreted preferentially inside the tumor. Initial derivatives of the platform deliver inside the tumor an antigenic trigger, antibody, or cytokine. They are also capable of vectoring other useful agents through engineering with heterologous genes encoding other molecules of therapeutic value.
- Bodywide Effect – Kymeris’ platform has shown a bodywide effect after subcutaneous or local administration. This could translate into less invasive administration protocols, including against multi-site or metastases from occult cancerous cells after surgery.
Late Pre-Clinical Stage
Kymeris Therapeutics is in the late pre-clinical stage of developing its Eukaryotic Immunotherapeutic Cancer Vaccine. The company has demonstrated proofs of principle in four pre-clinical murine models and created multiple derivatives that express or secrete constructs of therapeutic interest. Kymeris is now preparing to enter the clinical trial phase of development, which is an exciting step for the company and the cancer research community.
Conclusion
Kymeris Therapeutics is a Canadian biotech firm that is revolutionizing cancer treatment with its next-generation cellular immunotherapy platform against solid cancer. The company’s platform has demonstrated a significant effect on “cold” tumors and can overcome tumor microenvironment defenses. It also allows for flexible tumor-centric drug delivery and has shown a bodywide effect after subcutaneous or local administration. Kymeris is in the late pre-clinical stage of developing its Eukaryotic Immunotherapeutic Cancer Vaccine and is preparing to enter the clinical trial phase. The company’s innovative approach to cancer treatment has the potential to improve patient outcomes and make a significant impact on the field of cancer research.
Website: http://www.kymeris.net
LinkedIn: https://www.linkedin.com/company/40723696/
Looking to amplify your brand’s impact in Canada’s thriving startup and investment sector? Join the league of innovators, leaders, and decision-makers making a difference through Canada Venture News. Engage with our audience of startup founders, investors, and executives through sponsored articles and partnerships. Discover more on our Promotion & Sponsored Articles page or email us directly at [email protected]. Let’s shape your story together.
